We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Volatile Interest Rates Limit CME Group's (CME) Growth?
Read MoreHide Full Article
On Jun 23, 2016, we issued an updated research report on CME Group Inc. (CME - Free Report) .
The ongoing weakness in derivative markets and widening of spreads are hurting the top line and bottom line of CME Group. The first quarter of 2016 too witnessed a slight uptick in operating expenses.
Moreover, the revolving credit facilities, intense borrowing and note offerings could hamper the company’s capital position in the future. Also, higher impairment losses from acquired assets and interest costs continue to weigh on the bottom line.
Further, the securities exchange provider anticipates capital expenditure to range between $115 million and $120 million in 2016. Also, weak fundamentals and repayment of debt may limit CME Group’s ability to fund capital expenditure and pursue acquisitions or investments in new technologies.
CME Group’s diversified product portfolio is significantly exposed to extreme interest rate volatility, currency fluctuation, firm government regulations and limited credit availability in the currently unstable capital and credit markets. As a result, the company’s liquidity can be hampered. Also, if this trade scenario continues or worsens then the company might witness a fall in the customer demand.
The Zacks Consensus Estimate has also been witnessing downward revisions over the last 60 days for both 2016 and 2017. It declined 5% to $4.36 for 2016 and 1% to $4.70 for 2017.
Nonetheless, diverse derivative product lines, new products launches, modest capital position and effective capital deployment raise optimism.
In addition, efforts to promote, expand and cross-sell its core exchange-traded business through strategic alliances, meaningful acquisitions, new product initiatives and global presence support growth.
With respect to earnings performance, CME Group delivered positive surprise in three of the last four quarters with an average of about 2.4%. Zacks Rank and Stocks to Consider
Currently, CME Group carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the finance sector are Bats Global Markets , Markel Corp. (MKL - Free Report) and Cincinnati Financial Corp. (CINF - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Volatile Interest Rates Limit CME Group's (CME) Growth?
On Jun 23, 2016, we issued an updated research report on CME Group Inc. (CME - Free Report) .
The ongoing weakness in derivative markets and widening of spreads are hurting the top line and bottom line of CME Group. The first quarter of 2016 too witnessed a slight uptick in operating expenses.
Moreover, the revolving credit facilities, intense borrowing and note offerings could hamper the company’s capital position in the future. Also, higher impairment losses from acquired assets and interest costs continue to weigh on the bottom line.
Further, the securities exchange provider anticipates capital expenditure to range between $115 million and $120 million in 2016. Also, weak fundamentals and repayment of debt may limit CME Group’s ability to fund capital expenditure and pursue acquisitions or investments in new technologies.
CME Group’s diversified product portfolio is significantly exposed to extreme interest rate volatility, currency fluctuation, firm government regulations and limited credit availability in the currently unstable capital and credit markets. As a result, the company’s liquidity can be hampered. Also, if this trade scenario continues or worsens then the company might witness a fall in the customer demand.
CME GROUP INC Price and Consensus
CME GROUP INC Price and Consensus | CME GROUP INC Quote
The Zacks Consensus Estimate has also been witnessing downward revisions over the last 60 days for both 2016 and 2017. It declined 5% to $4.36 for 2016 and 1% to $4.70 for 2017.
Nonetheless, diverse derivative product lines, new products launches, modest capital position and effective capital deployment raise optimism.
In addition, efforts to promote, expand and cross-sell its core exchange-traded business through strategic alliances, meaningful acquisitions, new product initiatives and global presence support growth.
With respect to earnings performance, CME Group delivered positive surprise in three of the last four quarters with an average of about 2.4%.
Zacks Rank and Stocks to Consider
Currently, CME Group carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the finance sector are Bats Global Markets , Markel Corp. (MKL - Free Report) and Cincinnati Financial Corp. (CINF - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>